可操作药物基因组学与基本药物:WHO及非洲清单分析
该综述分析了WHO基本药物清单及52个非洲国家基本药物清单中具有可操作药物基因组学生物标志物检测推荐的系统性药物,并评估了8个非洲国家通过可用药品配方实现药物基因组学指导给药的可行性。结果显示,WHO清单447种药物中58种(13%)有可操作药物基因组学标志物,非洲国家清单平均每8种药物中1种有药物基因组学指导,8国可实施性为75%至96%。
要点
- WHO 2023基本药物清单447种药物中58种(13%)有可操作药物基因组学生物标志物检测推荐。
- 非洲国家基本药物清单中平均每8种药物有1种伴随既定药物基因组学指导。
- 8个非洲国家中基于药品配方和规格可实施药物基因组学指导给药的比例为75%至96%。
核心结论
- 将药物基因组学知识整合到基本药物遴选过程并确保适当药品配方可用,可提升非洲治疗安全性和有效性。
研究设计与样本
- 综述分析了WHO基本药物清单及52个非洲国家基本药物清单,并评估8个非洲国家药物基因组学指导给药的可行性。
主要发现
- WHO 2023基本药物清单包含447种独特系统性药物,其中58种(13%)有可操作药物基因组学生物标志物。
- 非洲国家基本药物清单合计包含774种此类药物,每国平均294种(范围125至465)。
- 非洲清单中此类药物最常见的类别为抗感染药(25.6%)、免疫调节剂/抗肿瘤药(16.7%)和精神行为障碍用药(14.1%)。
- 8个非洲国家基于产品配方和规格可实施药物基因组学指导给药的比例为75%至96%。
临床怎么用
- 临床药师在非洲基本药物清单药物遴选和用药决策中应关注可操作药物基因组学生物标志物检测推荐。
- 确保适当药品配方和规格可用,以支持药物基因组学指导下的剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The World Health Organization Model Essential Medicines List and African national essential medicines lists (EMLs) detail drugs intended to be consistently available within national health systems, thereby supporting clinicians and pharmacists in making evidence-based treatment decisions. At present, these EMLs do not account for pharmacogenomics, despite known drug-gene interactions and the considerable genetic diversity found throughout Africa. In the absence of pharmacogenomic considerations, the medicines lead to sub-optimal treatment outcomes, especially across a continent such as Africa which represents more genetic variation that the rest of the world combined. Herein, we review EMLs from the WHO, and from 52 African countries, highlighting systemic medicines for which actionable pharmacogenomic-biomarker testing recommendations exist. Furthermore, we assess the feasibility of PGx-guided dosing in eight African countries by examining the availability of registered drug formulations that facilitate dose adjustment. The 2023 WHO EML comprised 447 unique systemic medicines, with 58 (13%) categorized as medicines with actionable pharmacogenomic biomarkers. African country EMLs collectively featured 774 such medicines, with an average of 294 per country (range: 125-465). On average, for each country one in every eight medicines in the Essential Medicines List was associated with established pharmacogenomic guidance. PGx recommendation. Cumulatively in African EMLS the most frequent drug classes with this designation are anti-infectives (25.6%), immunomodulators/antineoplastics (16.7%), and medicines for mental and behavioral disorders (14.1%). Analysis of eight African countries determined that implementability ranged from 75% to 96% based on product formulation and strength availability to enable drug or dose modification. We provide data that contributes towards a foundation of increasing evidence showing that integrating pharmacogenomic knowledge into the selection processes for essential medicines and ensuring the availability of appropriate drug formulations can enhance treatment safety and efficacy across Africa.
引用
- Mazhindu TA, Nagy M, Twesigomwe D, et al. Actionable Pharmacogenomics and Essential Medicines: An Analysis of WHO and African Lists for Safer and Efficacious Drug Use. Clin Pharmacol Ther. 2026. PMID: 41932843. doi:10.1002/cpt.70268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。